Autres langues Virax Biolabs Group Limited

Actions

VRAX

KYG9495L1251

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 29/04/2024			Varia. 5j.	Varia. 1 janv.
0,6287 ^USD	-8,89 %		-10,82 %	-56,94 %

25/04	Virax Biolabs lance un portefeuille de solutions de profilage immunitaire évaluant l'immunité adaptative dans les syndromes post-viraux à ESCMID Global 2024.	CI
12/01	Virax Biolabs Group Limited publie ses résultats pour le semestre clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Virax Biolabs : Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 - Form 6-K	25/04
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	25/04
Virax Biolabs to Participate at ESCMID Global 2024	17/04
Virax Biolabs : to Participate at ESCMID Global 2024 - Form 6-K	16/04
Virax Biolabs : Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - Form 6-K	15/03
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	12/01
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	22/12
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	21/12
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation	15/12
Top Premarket Gainers	12/12
Virax Biolabs : Notice of 2023 Annual General Meeting of Shareholders To Be Held on - Form 6-K	08/11
Virax Biolabs : CLAWBACK POLICY - Form 6-K	31/10/23
Virax Biolabs Group Limited announced that it has received $2.15 million in funding	17/10/23
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding	12/10/23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar	13/09/23
Virax Biolabs : Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar - Form 6-K	12/09/23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum	04/09/23
Virax Biolabs Group Names Nigel McCracken Operating Chief.	01/09/23
Virax Biolabs Group Limited Announces Management Changes	01/09/23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid	04/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Virax Biolabs Group Limited

Actions

VRAX

KYG9495L1251

Autres langues

Filtres